THE ARISING · Longevity & Healthspan
Long COVID trial found a symptom signal, but did not use a sham device
November 17, 2026 · Longevity & Healthspan
A randomized trial tested whether a device that stimulates the vagus nerve through the skin, a structured sound program, or both could change symptoms in adults with long COVID. The Neuromodulation study was published October 8 and drew renewed attention after a November company announcement.
The four-week study compared the three interventions with monitoring alone. The journal report treated overall long COVID symptom burden as the primary outcome and a self-reported depressive symptom score as secondary. Depressive symptom scores improved in the active groups, but that secondary signal should not be read as proof that either intervention treats long COVID or depression.
Participants knew whether they were receiving an intervention, and the comparison group used no sham device or matching sound program. That makes it difficult to distinguish a specific treatment effect from expectations or extra attention. The published analysis also included only 250 of 541 people re-enrolled after a protocol change. It required completed outcomes and, in active groups, at least half of the scheduled use. Restricting the comparison after randomization can make the remaining groups less comparable.
The registry lists a slightly different enrollment total (546) and includes depression among its primary measures; the report uses the post-amendment enrollment and names depression as secondary. These records describe the study differently. A larger, blinded comparison with a credible sham and analysis that retains participants as randomized would be more informative. The lead investigator is a co-founder and executive of the device maker, and a co-author founded the company behind the sound program.